TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
D.Western Therapeutics Institute ( (JP:4576) ) has provided an announcement.
D. Western Therapeutics Institute has announced the completion of the observation period for subjects in the global phase III clinical study of their drug K-321, developed to treat Fuchs endothelial corneal dystrophy. This milestone marks a significant step forward in the drug’s development, as the data collected will now be analyzed to assess the drug’s efficacy and safety compared to a placebo. The company, in collaboration with Kowa Company, Ltd., aims to provide new treatment options for patients suffering from this condition, which currently has limited therapeutic options. The announcement does not affect the company’s earnings forecast for the fiscal year ending December 2025.
The most recent analyst rating on (JP:4576) stock is a Hold with a Yen98.00 price target. To see the full list of analyst forecasts on D.Western Therapeutics Institute stock, see the JP:4576 Stock Forecast page.
More about D.Western Therapeutics Institute
D. Western Therapeutics Institute, Inc. operates in the pharmaceutical industry, focusing on the development of ophthalmic solutions. Their primary product in development is K-321, an ophthalmic solution aimed at treating Fuchs endothelial corneal dystrophy, a condition that currently relies heavily on corneal transplantation for treatment.
Average Trading Volume: 4,379,613
Technical Sentiment Signal: Strong Sell
Current Market Cap: Yen5.37B
For detailed information about 4576 stock, go to TipRanks’ Stock Analysis page.